Free Trial

Molina Healthcare (NYSE:MOH) Releases Earnings Results, Misses Estimates By $0.02 EPS

Molina Healthcare logo with Medical background

Molina Healthcare (NYSE:MOH - Get Free Report) announced its earnings results on Wednesday. The company reported $5.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $5.50 by ($0.02), Zacks reports. The company had revenue of $11.43 billion for the quarter, compared to analyst estimates of $10.94 billion. Molina Healthcare had a return on equity of 27.84% and a net margin of 2.60%. The firm's revenue for the quarter was up 15.7% on a year-over-year basis. During the same period last year, the firm earned $5.86 earnings per share.

Molina Healthcare Stock Performance

NYSE:MOH traded up $6.61 during mid-day trading on Friday, hitting $164.83. 3,268,454 shares of the company's stock traded hands, compared to its average volume of 880,995. The firm has a 50 day moving average of $270.58 and a two-hundred day moving average of $297.10. Molina Healthcare has a 12 month low of $156.36 and a 12 month high of $365.23. The firm has a market capitalization of $8.93 billion, a price-to-earnings ratio of 8.13, a price-to-earnings-growth ratio of 1.17 and a beta of 0.55. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.87.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on MOH shares. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $210.00 target price (down from $312.00) on shares of Molina Healthcare in a research report on Friday. Sanford C. Bernstein began coverage on Molina Healthcare in a report on Tuesday, April 22nd. They issued an "outperform" rating and a $414.00 target price for the company. Barclays reduced their target price on Molina Healthcare from $270.00 to $186.00 and set an "equal weight" rating for the company in a report on Friday. Guggenheim began coverage on Molina Healthcare in a report on Wednesday, April 9th. They issued a "neutral" rating for the company. Finally, Baird R W lowered Molina Healthcare from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 15th. Twelve research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $267.42.

View Our Latest Research Report on MOH

Insider Activity at Molina Healthcare

In related news, CEO Joseph M. Zubretsky sold 87,500 shares of the stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $320.06, for a total transaction of $28,005,250.00. Following the completion of the sale, the chief executive officer owned 257,715 shares in the company, valued at $82,484,262.90. This represents a 25.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Richard M. Schapiro sold 669 shares of the stock in a transaction that occurred on Tuesday, April 29th. The shares were sold at an average price of $320.50, for a total value of $214,414.50. Following the sale, the director owned 11,244 shares of the company's stock, valued at approximately $3,603,702. The trade was a 5.62% decrease in their position. The disclosure for this sale can be found here. 1.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Molina Healthcare

A number of institutional investors have recently added to or reduced their stakes in MOH. Baird Financial Group Inc. acquired a new stake in Molina Healthcare during the first quarter worth about $210,000. NewEdge Advisors LLC grew its position in Molina Healthcare by 33.4% during the first quarter. NewEdge Advisors LLC now owns 1,106 shares of the company's stock worth $364,000 after buying an additional 277 shares in the last quarter. Jones Financial Companies Lllp grew its position in Molina Healthcare by 713.3% during the first quarter. Jones Financial Companies Lllp now owns 1,651 shares of the company's stock worth $544,000 after buying an additional 1,448 shares in the last quarter. Focus Partners Wealth grew its position in Molina Healthcare by 82.7% during the first quarter. Focus Partners Wealth now owns 3,749 shares of the company's stock worth $1,235,000 after buying an additional 1,697 shares in the last quarter. Finally, Woodline Partners LP acquired a new stake in Molina Healthcare during the first quarter worth about $1,541,000. 98.50% of the stock is owned by institutional investors and hedge funds.

About Molina Healthcare

(Get Free Report)

Molina Healthcare, Inc provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.

Featured Articles

Earnings History for Molina Healthcare (NYSE:MOH)

Should You Invest $1,000 in Molina Healthcare Right Now?

Before you consider Molina Healthcare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Molina Healthcare wasn't on the list.

While Molina Healthcare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle
3 Small-Cap Biotech Stocks With Catalysts Too Big to Ignore

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines